Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
Significance: Anti–CTLA-4 mAb is able to augment tumor immunity despite CTLA-4 expression by functionally opposing T cell populations: activated effector T (Teff) cells and FOXP3 + CD4 + Treg cells. Here we show that anti–CTLA-4 mAb engineered to be cytotoxic depleted Treg cells effectively in vitro in humans and in vivo in mice. It expanded antigen-specific CD8 + Teff cells when tumor-antigen stimulation was delayed several days to protect them from killing by the mAb. Anti–CTLA-4 mAb modified to exhibit a lesser or no cell-depleting activity failed to show such effects. This strategy of differentially controlling Treg and Teff cells by cytotoxic anti–CTLA-4 mAb to evoke effective tumor immunity will help in designing cancer immunotherapy targeting other molecules commonly expressed by Treg and Teff cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“New studies suggest that CTLA4 blockade within the TME could decrease the activation threshold of T cells while selectively depleting immunosuppressive regulatory T cells, which can increase the number of tumor‐specific CD8+ T cells [294].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [294]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 2×
“In agreement with these results, simultaneous treatment of ipilimumab and gp100 peptide vaccine in patients with metastatic melanoma showed slight reductions in overall survival compared with ipilimumab alone, suggesting that melanoma-antigen specific CD8 T cells with elevated CTLA-4 expression might have been concurr…”
BackgroundResultCuriel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 1×
“Anti-human CTLA-4 mAb, which has been shown to be clinically effective in treating melanoma (17, 18), was initially considered to block CTLA-4–mediated negative signal into activated effector T cells, sustaining their activated state in attacking tumor cells.”
BackgroundSakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306 · cited 1×
“N occurring CD25 CD4 Treg cells, which express the transcription factor FOXP3, play indispensable roles in the maintenance of immunological self-tolerance and homeostasis (1).”
BackgroundSelf-citationCTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956 · cited 1×
“One of various suppression mechanisms used by Treg cells is CTLA-4–dependent down-regulation of CD80 and CD86 expression by dendritic cells (DCs) (14, 15).”
BackgroundSelf-citationFcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Miyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.019 · Cited by 2,291 · cited 2×
“II eTreg cells, which highly express CTLA-4 (10).”
BackgroundSelf-citationRegulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860
Regulatory T cells in cancer immunotherapy
Tanaka, A., & Sakaguchi, S. (2017) · Cell Research · doi:10.1038/cr.2016.151 · Cited by 1,860
Self-citation
Cited by
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Regulatory T Cells and Human Disease
Sakaguchi, S., Mikami, N., Wing, J. B., Tanaka, A., Ichiyama, K., & Ohkura, N. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041717 · Cited by 1,120
Self-citationPD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
Kamada, T., Togashi, Y., Tay, C., Ha, D., Sasaki, A., Nakamura, Y., Sato, E., Fukuoka, S., Tada, Y., Tanaka, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1822001116 · Cited by 1,008
“These data suggest that antibodies, especially cell-depleting ones, targeting CTLA-4, OX-40, and CCR4 can be used for the treatment and prevention of HPD by specifically depleting eTreg cells (28).”
BackgroundSelf-citationLi, C., Jiang, P., Wei, S., Xu, X., & Wang, J. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01234-1 · Cited by 921
“However, the ADCC strategy is unlikely to succeed in colorectal, liver, prostate and ovarian cancer treatments [170, 171].”
BackgroundChauvin, J.-M., & Zarour, H. M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000957 · Cited by 794
“59 Because Tregs highly express TIGIT in the TME, one wonders whether anti-TIGIT mAbs with Fc-binding capability induce Treg depletion.”
Background
Metadata
- Authors
- Ha, D., Tanaka, A., Kibayashi, T., Tanemura, A., Sugiyama, D., Wing, J. B., Lim, E. L., Teng, K. W. W., Adeegbe, D., Newell, E. W., Katayama, I., Nishikawa, H., & Sakaguchi, S.
- Affiliations
- Kyoto University (JP)
- Immunology Frontier Research Center, The University of Osaka (JP)
- Chugai Pharmaceutical Co., Ltd. (Japan) (JP)
- The University of Osaka (JP)
- Agency for Science, Technology and Research (SG)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2018-12-26
- Volume
- 116
- Issue
- 2
- Pages
- 609-618
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC6329979
- OpenAlex
- W2907885272
- Cited by
- 205
- References
- 37
- Citations by year
- 2026: 11 · 2025: 25 · 2024: 31 · 2023: 22 · 2022: 41 · 2021: 24 · 2020: 33 · 2019: 17
- FWCI
- 6.94
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- OUKA (Osaka University Knowledge Archive) (Osaka University) (submittedVersion)
- Funders
- MEXT | Japan Society for the Promotion of Science (16H006295)
- Japan Agency for Medical Research and Development (JP18cm0106303)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- anti-CTLA-4 antibody, CTLA-4, regulatory T cells, Foxp3, effector T cells, CD8+ T cells, antitumor immunity, cancer immunotherapy, Fc-engineered antibody, antibody cytotoxicity, Treg depletion
- MeSH terms
- Antineoplastic Agents, Immunological, Animals, Antibody-Dependent Cell Cytotoxicity, Humans, Mice, Inbred BALB C, Neoplasms, CD8-Positive T-Lymphocytes, Cancer Vaccines, T-Lymphocytes, Regulatory, Mice, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody. https://app.cochat.ai/papers/10.1073/pnas.1812186116
- The paper
- Ha, D., Tanaka, A., Kibayashi, T., Tanemura, A., Sugiyama, D., Wing, J. B., Lim, E. L., Teng, K. W. W., Adeegbe, D., Newell, E. W., Katayama, I., Nishikawa, H., & Sakaguchi, S. (2019). Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1812186116
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.